Phase II study of plitidepsin 3-hour infusion every 2 weeks in patients with unresectable advanced medullary thyroid carcinoma

American Journal of Clinical Oncology: Cancer Clinical Trials

Volumn 33, Issue 1, 2010, Pages 83-88

  Baudin, Eric ^a   Droz, Jean P ^b   Paz Ares, Luis ^c   Van Oosterom, Allan T ^d   Cullell Young, Martin ^e   Schlumberger, Martin ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

^b CENTRE LÉON BÉRARD   (France)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d UZ Gasthuisberg   (Netherlands)

^e Pharma Mar ^*  (Spain)

Author keywords

Aplidin; Medullary thyroid carcinoma; Phase II; Plitidepsin

Indexed keywords

CALCITONIN; CARBOPLATIN; CARCINOEMBRYONIC ANTIGEN; CARNITINE; CYCLODEPSIPEPTIDE; DEHYDRODIDEMNIN B; DEXAMETHASONE; GRANISETRON; LOW MOLECULAR WEIGHT HEPARIN; MITOMYCIN C; NITROSOUREA; ONDANSETRON; PLITIDEPSIN; SOMATOSTATIN DERIVATIVE; UNCLASSIFIED DRUG;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CREATINE KINASE BLOOD LEVEL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; FATIGUE; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; HYPERSENSITIVITY; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOPENIA; LYMPHOCYTOPENIA; MALE; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; MYALGIA; NAUSEA; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PROTEIN STABILITY; QUALITY OF LIFE; SIDE EFFECT; THORAX PAIN; THROMBOCYTOPENIA; THROMBOSIS; THYROID MEDULLARY CARCINOMA; TREATMENT RESPONSE; TUMOR VOLUME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; BRAIN STEM NEOPLASMS; DEPSIPEPTIDES; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE; THYROID NEOPLASMS; TREATMENT OUTCOME;

EID: 76749105187     PISSN: 02773732     EISSN: 1537453X     Source Type: Journal    
DOI: 10.1097/COC.0b013e31819fdf5e     Document Type: Article

References (33)

1. Albores-Saavedra J, Monforte H, Nadji M, et al. C-cell hyperplasia in thyroid tissue adjacent to follicular cell tumors. Hum Pathol. 1988;19:795-799.
2. Schmutzler C, Koehrle J. Innovative strategies for the treatment of thyroid cancer. Eur J Endocrinol. 2000;143:15-24.
3. Traugott A, Moley JF. Medullary thyroid cancer: medical management and follow-up. Curr Treat Options Oncol. 2005;6:339-346.
4. Simpson WJ. Radioiodine and radiotherapy in the management of thyroid cancers. Otolaryngol Clin North Am. 1990;23:509-521.
5. Brierley JD, Tsang RW. External radiation therapy in the treatment of thyroid malignancy. Endocrinol Metab Clin North Am. 1996;25:141-157.
6. Bergholm U, Bergstrom R, Ekbom A. Long-term follow-up of patients with medullary carcinoma of the thyroid. Cancer. 1997;79:132-138.
7. Kebebew E, Ituarte PH, Siperstein AE, et al. Medullary thyroid carcinoma: clinical characteristics, treatment, prognostic factors, and a comparison of staging systems. Cancer. 2000;88:1139-1148.
8. Cuadrado A, Garcia-Fernandez LF, Gonzalez L, et al. Aplidin induces apoptosis in human cancer cells via glutathione depletion and sustained activation of the epidermal growth factor receptor, Src, JNK, and p38 MAPK. J Biol Chem. 2003;278:241-250.
9. Biscardi M, Caporale R, Balestri F, et al. VEGF inhibition and cytotoxic effect of aplidin in leukemia cell lines and cells from acute myeloid leukemia. Ann Oncol. 2005;16:1667-1674.
10. Gonzalez-Santiago L, Suarez Y, Zarich N, et al. Aplidin induces JNKdependent apoptosis in human breast cancer cells via alteration of glutathione homeostasis, Rac1 GTPase activation, and MKP-1 phosphatase down regulation. Cell Death Differ. 2006;13:1968-1981.
11. Munoz-Alonso MJ, Gonzalez-Santiago L, Zarich N, et al. Plitidepsin has a dual effect inhibiting cell cycle and inducing apoptosis via Rac1/c-Jun NH2-terminal kinase activation in human melanoma cells. J Pharmacol Exp Ther. 2008;324:1093-1101.
12. Turner HE, Harris AL, Melmed S, et al. Angiogenesis in endocrine tumors. Endocr Rev. 2003;24:600-632.
13. Depenbrock H, Peter R, Faircloth GT, et al. In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and hematopoietic precursor cells. Br J Cancer. 1998;78: 739-744.
14. Lobo C, Garcia-Pozo SC, Nunez DC, et al. Effect of dehydrodidemnin B on human colon carcinoma cell lines. Anticancer Res. 1997;17:333-336.
15. Urdiales JL, Morata P, Nunez DC, et al. Antiproliferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett. 1996;102:31-37.
16. Faivre S, Chieze S, Delbaldo C, et al. Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol. 2005;23:7780-7782.
17. Anthoney A, Paz-Ares L, Twelves C. Phase I and pharmacokinetic (PK) study of Aplidin (APL) using a 24-hour, weekly schedule. Proc Am Soc Clin Oncol. 2000. Abstract 734.
18. Ciruelos EM, Twelves C, Dominguez MJ, et al. Phase I clinical and pharmacokinetic study of the marine compound Aplidin (APL) administered as a 3 hour infusion every 2 weeks. Proc Am Soc Clin Oncol. 2002. Abstract 422.
19. Maroun JA, Belanger K, Seymour L, et al. Phase I study of Aplidine in a dailyx5 one-hour infusion every 3 weeks in patients with solid tumors refractory to standard therapy. A National Cancer Institute of Canada Clinical Trials Group study: NCIC CTG IND 115. Ann Oncol. 2006;17:1371-1378.
20. Izquierdo MA, Bowman A, Garcia M, et al. Phase I clinical and pharmacokinetic study of plitidepsin as a 1-hour weekly intravenous infusion in patients with advanced solid tumors. Clin Cancer Res. 2008;14:3105-3112.
21. Jimeno J, Lopez-Martin JA, Ruiz-Casado A, et al. Progress in the clinical development of new marine-derived anticancer compounds. Anticancer Drugs. 2004;15:321-329.
22. ASCO. Update of recommendations for the use of hematopoietic colonystimulating factor: evidence-based clinical practice guidelines. J Clin Oncol. 1996;14:1957-1960.
23. Ball D, Baylin S, de Bustros A. The Thyroid: A Fundamental and Clinical Text. 7th ed. Philadelphia, PA: Lippincott-Raven; 1996.
24. Fleming JB, Lee JE, Bouvet M, et al. Surgical strategy for the treatment of medullary thyroid carcinoma. Ann Surg. 1999;230:697-707.
25. Cella DF, Tulsky DS, Gray G, et al. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570-579.
26. Gehan EA. The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. J Chronic Dis. 1961;13:346-353.
27. Schlumberger M, Abdelmoumene N, Delisle MJ, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 1995;71:363-365.
28. Nocera M, Baudin E, Pellegriti G, et al. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs a Calcitonine (GETC). Br J Cancer. 2000;83:715-718.
29. Bajetta E, Rimassa L, Carnaghi C, et al. 5-Fluorouracil, dacarbazine, and epirubicin in the treatment of patients with neuroendocrine tumors. Cancer. 1998;83:372-378.
30. Wells SY, Lakhani V, Hou J. A phase II trial of ZD6474 in patients with hereditary metastatic medullaty thyroid cancer. J Clin Oncol. 2006;24:5553.
31. Kim S, Rosen LS, Cohen EE, et al. A phase 2 study of Axitinib (AG-013736), a potent inhibitor of VEGFRs, in patients with advanced thyroid cancer. Ann Oncol. 2006;17:579A.
32. Eisen T, Thatcher N, Leyvraz S, et al. Phase II study of weekly plitidepsin as second-line therapy for small cell lung cancer. Lung Cancer. 2009;64: 60-65.
33. Peschel C, Hartmann JT, Schmittel A, et al. Phase II study of plitidepsin in pretreated patients with locally advanced or metastatic non-small-cell lung cancer. Lung Cancer. 2008;60:374-380.